Project Manager of Cell Biology and Biochemistry
He took his Graduation at the Biological Chemical Professional Institute IPSIA of Pomezia. He joined Merck Research Laboratories in 1996 and was staff biochemist in the Oncology Department, where he worked on numerous small molecule drug discovery projects in the areas of enzymology and cell biology. In Exiris he extended his expertise in the field of antibodies.
She took her Bachelor and Master Degree in Biology in 2017. She was selected for an industrial Ph.D. project in “Molecular and Translational Oncology and Innovative Medical Technologies” at the Magna Grecia University of Catanzaro, that she conducted in Rome at Exiris with a secondment at Groningen University. She has come back to Exiris as Senior Scientist.
Antibody Facility Manager
She graduated in Biological Sciences at the University of Rome “Tor Vergata”, where she also obtained her PhD in Medical Genetics. From 2002 to 2015 she had a contract work at the Istituto Dermopatico dell’Immacolata (IDI) working on the autoimmune disease epidermolysis bullosa. She joined Exiris in 2015, where she is in charge of the Antibody Production Facility.
GIAN MARCO VITA
He took his Bachelor’s Degree in Biologicals Sciences at the University of Rome “Roma Tre” in 2015. At the same University he also obtained his Master’s Degree in Biology for Molecular, Cellular and Physio-Pathologic Research which was conducted in collaboration with IRBM Science Park in Pomezia. After a stage in Prof. Hutter’s Laboratory of Brain Tumor Immunotherapy at the University of Basel, he went back to Italy where he obtained his PhD at Roma Tre University of Rome. He joined Exiris in 2022 as a Post Doc working on ADCs of Exiris’s pipeline.
ALVARO FELIZ MOREL
During his BSc in Biology at Complutense University of Madrid (Spain) he was awarded with an Erasmus+ Scholarship that allowed him to travel to Nice and start the first year of Master. After obtaining his BSc, he returned to Nice to finish his MSc in Living Sciences (specialty in Genetics and Development). He was selected for a PhD position as an Early Stage Researcher at Exiris in the ETN Magicbullet Reloaded European Training Network, a consortium working on small molecule-drug conjugates (SMDCs) with a special focus on drugs capable to stimulate tumor immune responses and overcome resistance to immuno-therapy.